Structure Therapeutics (GPCR) CDO reports tax share and ESPP transactions

Rhea-AI Filing Summary

Structure Therapeutics Inc.'s Chief Development Officer Ashley Hall reported several routine share movements. On March 3, 2026, Hall disposed of 4,836 Ordinary Shares at $20.99 per share to cover income taxes on a vesting restricted share unit award, leaving 107,481 Ordinary Shares directly owned.

Earlier, Hall acquired 225 American Depositary Shares (ADSs) on May 20, 2025 and 237 ADSs on November 20, 2025 through the company’s Employee Share Purchase Plan. Each ADS represents three Ordinary Shares and is convertible into Ordinary Shares at any time with no expiration date.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider Hall Ashley

Role Chief Development Officer

Type	Security	Shares	Price	Value
Tax Withholding	Ordinary Shares	4,836	$20.99	$102K
Grant/Award	American Depositary Shares	237	$0.00	--
Grant/Award	American Depositary Shares	225	$0.00	--

Holdings After Transaction: Ordinary Shares — 107,481 shares (Direct); American Depositary Shares — 462 shares (Direct)

Footnotes (1)

1. The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents three Ordinary Shares of the Issuer. Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of a restricted share unit award. Each ADS is convertible at any time, at the holder's election, into three Ordinary Shares of the Issuer. The ADSs have no expiration date. Voluntary reporting of the acquisition of 225 ADSs by the Reporting Person on May 20, 2025 pursuant to the Issuer's Employee Share Purchase Plan. Voluntary reporting of the acquisition of 237 ADSs by the Reporting Person on November 20, 2025 pursuant to the Issuer's Employee Share Purchase Plan.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hall Ashley

(Last) (First) (Middle)

C/O STRUCTURE THERAPEUTICS INC.

601 GATEWAY BLVD., SUITE 900

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Structure Therapeutics Inc. [ GPCR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Development Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares(1)	03/03/2026		F		4,836(2)	D	$20.99	107,481	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
American Depositary Shares	(3)	05/20/2025		A(4)	V	225		(3)	(3)	Ordinary Shares(1)	675	$0	225	D
American Depositary Shares	(3)	11/20/2025		A(5)	V	237		(3)	(3)	Ordinary Shares(1)	711	$0	462	D

Explanation of Responses:

1. The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents three Ordinary Shares of the Issuer.

2. Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of a restricted share unit award.

3. Each ADS is convertible at any time, at the holder's election, into three Ordinary Shares of the Issuer. The ADSs have no expiration date.

4. Voluntary reporting of the acquisition of 225 ADSs by the Reporting Person on May 20, 2025 pursuant to the Issuer's Employee Share Purchase Plan.

5. Voluntary reporting of the acquisition of 237 ADSs by the Reporting Person on November 20, 2025 pursuant to the Issuer's Employee Share Purchase Plan.

	/s/ Jun Yoon, Attorney-in-Fact	03/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did GPCR executive Ashley Hall report?

Ashley Hall reported a tax-related disposition of 4,836 Ordinary Shares and two prior Employee Share Purchase Plan acquisitions of ADSs. These moves reflect compensation and tax withholding events rather than open-market trading, and leave Hall with 107,481 Ordinary Shares held directly after the March 2026 transaction.

How many Structure Therapeutics (GPCR) shares did Ashley Hall dispose of for taxes?

Hall disposed of 4,836 Ordinary Shares at $20.99 per share. The shares were withheld by Structure Therapeutics to satisfy income tax obligations tied to the vesting of a restricted share unit award, a common administrative step rather than a discretionary sale in the open market.

What Employee Share Purchase Plan acquisitions did GPCR’s Ashley Hall report?

Hall voluntarily reported acquiring 225 ADSs on May 20, 2025 and 237 ADSs on November 20, 2025 under Structure Therapeutics’ Employee Share Purchase Plan. These award-type acquisitions carried a stated price of $0.00 per ADS in the filing and increased Hall’s derivative holdings over time.

What is the relationship between Structure Therapeutics ADSs and Ordinary Shares?

The filing states that each American Depositary Share (ADS) represents three Ordinary Shares of Structure Therapeutics. Each ADS is convertible at any time, at the holder’s election, into three Ordinary Shares, and the ADSs have no expiration date, providing ongoing flexibility for conversion.

How many Ordinary Shares does Ashley Hall hold after the latest GPCR transaction?

Following the March 3, 2026 tax-withholding disposition, Ashley Hall directly owns 107,481 Ordinary Shares of Structure Therapeutics. This figure reflects the remaining Ordinary Shares after 4,836 shares were withheld by the company to cover income tax obligations from a vesting restricted share unit award.